Creative Planning decreased its stake in Myriad Genetics, Inc. (NASDAQ:MYGN) by 2.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,200 shares of the company’s stock after selling 171 shares during the period. Creative Planning’s holdings in Myriad Genetics were worth $160,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Albert D Mason Inc. raised its position in shares of Myriad Genetics by 1.5% in the first quarter. Albert D Mason Inc. now owns 16,382 shares of the company’s stock worth $315,000 after buying an additional 250 shares during the last quarter. Commerzbank Aktiengesellschaft FI raised its position in shares of Myriad Genetics by 1.7% in the first quarter. Commerzbank Aktiengesellschaft FI now owns 21,733 shares of the company’s stock worth $417,000 after buying an additional 357 shares during the last quarter. Foundry Partners LLC raised its position in shares of Myriad Genetics by 3.6% in the first quarter. Foundry Partners LLC now owns 22,500 shares of the company’s stock worth $432,000 after buying an additional 775 shares during the last quarter. Fox Run Management L.L.C. raised its position in shares of Myriad Genetics by 6.8% in the first quarter. Fox Run Management L.L.C. now owns 18,268 shares of the company’s stock worth $351,000 after buying an additional 1,168 shares during the last quarter. Finally, Fisher Asset Management LLC raised its position in shares of Myriad Genetics by 2.1% in the first quarter. Fisher Asset Management LLC now owns 61,011 shares of the company’s stock worth $1,171,000 after buying an additional 1,280 shares during the last quarter.

Myriad Genetics, Inc. (NASDAQ MYGN) traded up 1.783% during mid-day trading on Friday, hitting $27.685. 480,670 shares of the stock were exchanged. Myriad Genetics, Inc. has a 52-week low of $15.15 and a 52-week high of $28.39. The company has a 50 day moving average price of $25.14 and a 200 day moving average price of $20.84. The firm has a market cap of $1.89 billion, a price-to-earnings ratio of 59.156 and a beta of 0.31.

Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings data on Tuesday, August 8th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.04. The company had revenue of $200.50 million for the quarter, compared to analysts’ expectations of $193.71 million. Myriad Genetics had a net margin of 2.83% and a return on equity of 9.67%. Myriad Genetics’s revenue was up 7.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.36 EPS. On average, analysts anticipate that Myriad Genetics, Inc. will post $1.05 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This story was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.watchlistnews.com/myriad-genetics-inc-nasdaqmygn-stake-decreased-by-creative-planning/1475824.html.

A number of research analysts have issued reports on MYGN shares. BidaskClub lowered shares of Myriad Genetics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 19th. Zacks Investment Research upgraded shares of Myriad Genetics from a “hold” rating to a “buy” rating and set a $28.00 price target on the stock in a research note on Monday, July 17th. Barclays PLC cut their price target on shares of Myriad Genetics from $28.00 to $26.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Jefferies Group LLC restated a “hold” rating and set a $23.00 price target (up previously from $21.00) on shares of Myriad Genetics in a research note on Thursday. Finally, Piper Jaffray Companies restated a “hold” rating and set a $22.00 price target on shares of Myriad Genetics in a research note on Friday, July 14th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have assigned a buy rating to the company. The company has an average rating of “Hold” and an average target price of $21.78.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics, Inc. (NASDAQ:MYGN).

Institutional Ownership by Quarter for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.